<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034446</url>
  </required_header>
  <id_info>
    <org_study_id>HY004001</org_study_id>
    <nct_id>NCT04034446</nct_id>
  </id_info>
  <brief_title>CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)</brief_title>
  <official_title>a Feasibility and Safety Study of Bispecific CD19-CD22 CAR-T Cell in the Treatment of Relapsed or Refractory B-ALL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juventas Cell Therapy Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, single center study to determine the safety and efficacy of&#xD;
      CD19-CD22 CAR-T cells in patients with CD19+CD22+ Leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, open-label, single center study to determine the safety and efficacy of&#xD;
      CD19-CD22 CAR-T cells in patients with relapsed or refractory B-ALL. The study will have the&#xD;
      following sequential phases: Screening, Pre-Treatment (Cell Product Preparation &amp;&#xD;
      Lymphodepleting Chemotherapy), Treatment and Follow-up, and Survival Follow-up. The total&#xD;
      duration of the study is 2 years from CD19-CD22 CAR-T cell infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall remission rate (ORR)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response at Day 28 days</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who achieve complete remission (CR) or complete remission with incomplete blood count recovery (CRi) at month 6 without SCT between CD19-CD22 CAR-T cells infusion and Month 6 response assessment.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who achieve CR or CRi with minimal residual disease (MRD) negative bone marrow</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of CD19-CD22 CAR-T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19-CD22 CAR-T cells</intervention_name>
    <description>0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent is signed by a subject or his lineal relation.&#xD;
&#xD;
          2. Age 3 and older.&#xD;
&#xD;
          3. Documentation of cluster of differentiation 19 (CD19) and or cluster of&#xD;
             differentiation 19 (CD22) expression on leukemic blasts in the BM, peripheral blood&#xD;
             within 3 months of screening.;&#xD;
&#xD;
          4. Relapsed or refractory B-cell ALL&#xD;
&#xD;
               -  Relapse within 12 months of first remission&#xD;
&#xD;
               -  Without remission after 2 cycles of induction chemotherapy regimen.&#xD;
&#xD;
               -  Without remission or relapse after salvage treatments.&#xD;
&#xD;
               -  Any BM relapse after autologous stem cell transplantation (ASCT).&#xD;
&#xD;
          5. Without remission or relapse after any prior CD19 targeted therapy;&#xD;
&#xD;
          6. Patients with Philadelphia chromosome positive (Ph+) ALL are eligible if they are&#xD;
             intolerant to or have failed 2 lines of tyrosine kinase inhibitor therapy (TKI); no&#xD;
             TKI salvage treatments if the patient has a BCR-ABL1 kinase domain gatekeeper mutation&#xD;
             Thr315Ile (T315I) mutation.&#xD;
&#xD;
          7. Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening；&#xD;
&#xD;
          8. Eastern cooperative oncology group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          9. Adequate organ function defined as:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) ≤3 upper limit of normal (ULN);&#xD;
&#xD;
               -  Serum alanine aminotransferase (ALT) ≤3 ULN;&#xD;
&#xD;
               -  Total bilirubin ≤ 2 ULN, except in individuals with Gilbert's syndrome;&#xD;
&#xD;
               -  Note: Patients with Gilbert's syndrome that bilirubin ≤ 3 ULN and direct&#xD;
                  bilirubin ≤ 1.5 ULN will be eligible.&#xD;
&#xD;
               -  A serum creatinine≤ 1.5 ULN or Creatine removal rate ≥ 60mL/min（Cockcroft and&#xD;
                  Gault）&#xD;
&#xD;
               -  Must have a minimum level of pulmonary reserve as ≤ Grade 1 dyspnea and oxygen&#xD;
                  saturation &gt; 91% on room air.&#xD;
&#xD;
               -  Absolute lymphocyte count ≥0.3 x 10⁹/L.&#xD;
&#xD;
         10. Women of child-bearing potential and all male participants must use highly effective&#xD;
             methods of contraception for a period of 1 year after the CD19-CD22 CAR-T cells&#xD;
             infusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active central nervous system leukemia&#xD;
&#xD;
          2. Patients with evidence of currently uncontrollable serious active infections (e.g.,&#xD;
             sepsis, bacteremia, fungemia, viremia, etc.).&#xD;
&#xD;
          3. Patients who are positive for any of HIV antibody, TP antibody, hepatitis B surface&#xD;
             antigen (HBsAg) and hepatitis C virus (HCV) antibody.&#xD;
&#xD;
          4. Major surgery within ≤ 4 weeks before enrollment.&#xD;
&#xD;
          5. Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative&#xD;
             intent.&#xD;
&#xD;
          6. Impaired cardiac function:&#xD;
&#xD;
               -  Left Ventricular Ejection Fraction (LVEF) ≤45%;&#xD;
&#xD;
               -  III/IV congestive heart failure (NYHA);&#xD;
&#xD;
               -  Severe arrhythmia (except for Atrial fibrillation, Paroxysmal supraventricular&#xD;
                  tachycardia);&#xD;
&#xD;
               -  Corrected QT interval (QTc) ≥450ms (male) or QTc≥470ms (female)（QTc using&#xD;
                  Bazett's formula (QTcB)=QT/RR^0.5）;&#xD;
&#xD;
               -  Myocardial infarction or Coronary Artery Bypass Graft Surgery, heart stent&#xD;
                  surgery.&#xD;
&#xD;
               -  Other heart diseases that have been judged by the investigator to be unsuitable&#xD;
                  for receiving cell therapy.&#xD;
&#xD;
          7. Patients with a history of epilepsy or other active central nervous system diseases.&#xD;
&#xD;
          8. Life expectancy &lt; 12 weeks.&#xD;
&#xD;
          9. Allergy to macromolecule biopharmaceuticals such as antibodies or cytokines.&#xD;
&#xD;
         10. Subjects who are receiving systemic steroid treatment and who have been determined by&#xD;
             the researchers to require long-term treatment with systemic steroids during&#xD;
             treatment, and subjects treated with systemic steroids must be excluded &lt; 72 hours&#xD;
             prior to CNCT19 infusion (except inhalation or local use).&#xD;
&#xD;
         11. Patients with other conditions making the patients unsuitable for receiving cell&#xD;
             therapy as judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>wang, jianxiang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>B-ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

